Designed to support the many stages of the research planning cycle, Elsevier's SciVal® suite of solutions provides information about research performance, funding and expertise to enable informed decision-making and drive successful outcomes. Serving research institutions, funding agencies and policy bodies, SciVal delivers objective analytical capabilities that can enhance the performance of individuals, teams and organizations. SciVal integrates institutional and external data sources with information from Elsevier's Scopus®, the standard for bibliometric research tools, to offer trusted solutions including SciVal Experts, SciVal Funding, SciVal Spotlight, SciVal Strata, SciVal Analytics and Pure. http://www.info.scival.com
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.Media contact Christopher James Elsevier +31-20-485-3243 email@example.com SOURCE Elsevier